Cambridge Healthtech Institute’s Inaugural

Informatics for Cancer Immunotherapies

August 6-7, 2019



Clinical success of immunomodulatory cancer therapies has sparked fast-paced growth in cancer research that converges at the intersection of cancer genomics, immunology, and informatics. Immuno-oncology is data-driven, yet the much-needed informatics techniques for integrating tumor analysis, tumor microenvironment, systemic immunity, and therapeutic response are at the early stages of development. Cambridge Healthtech Institute’s Inaugural Informatics for Cancer Immunotherapies convenes stakeholders that share their journey to this intersection of data and immuno-oncology – the place where breakthroughs happen.

ONCOLOGY DATA MANAGEMENT & ANALYTICAL TOOLS

Artificial Intelligence Accelerants in Oncology Informatics
Jonathan Dry, PhD, Director of Bioinformatics, Oncology, AstraZeneca

Integrating Oncology Data for Models of Cancer Dynamics
Doron Levy, PhD, Professor, Department of Mathematics, University of Maryland

High-Throughput Cancer Hypothesis Testing with an Integrated PhysiCell-EMEWS Workflow
Paul Macklin, PhD, Associate Professor, Intelligent Systems Engineering, Indiana University

Relevance of Patient Tumor Heterogeneity Defined by Robust Data Analytics
Patrice M. Milos, PhD, Co-Founder/President and CEO, Medley Genomics, Inc.

DATA GUIDES NOVEL IMMUNOTHERAPEUTIC STRATEGIES

Machine Learning in CAR T-Cell Therapy
Allen Xue, PhD, Director, Biostatistics, Kite, a Gilead Company

The Role of Macrophage Differentiation in Triple Negative Breast Cancer: A Multiscale Computational Modeling Approach
Kerri-Ann Norton, PhD, Assistant Professor, Computer Science Program, Department of Science, Mathematics, and Computing, Bard College

DeepTCR: A Deep Learning Framework for Revealing Structural Concepts within TCR Repertoire
John-William Sidhom, MSE, MD/PhD Candidate, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Biomedical Engineering, Johns Hopkins University School of Medicine

DATA GUIDES CLINICAL TRIALS & PATIENT SELECTION

CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana Farber Cancer Institute


For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
Email: mabrown@cambridgeinnovationinstitute.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com